Clinical Trial Update: Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fasting Condition [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 bioequivalence study of Ondansetron 8 mg tablets under fasting conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting
• Nausea and Vomiting
• Postoperative Nausea and Vomiting

Drugs mentioned

• Ondansetron (ondansetron)

Snippet

Sponsor: IPCA Laboratories Ltd. | Conditions: Fasting State | Phase 1 | Status: COMPLETED